FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Breckenridge Pharmaceutical Duloxetine Delayed-Release Capsules Recall

Duloxetine Delayed-Release Capsules USP, 30 mg, a

Breckenridge Pharmaceutical, Inc · Berlin, CT

Risk level
Class II
Reported by FDA
Apr 30, 2025
Recall ID
D-0388-2025
Check your lot numberHow we source this data

Summary

Breckenridge Pharmaceutical recalled Duloxetine Delayed-Release Capsules starting Apr 14, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0388-2025 on Apr 30, 2025. Reason: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Product description

Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922

Lot numbers, UPCs & expiration codes

Lot # 230201C, exp. date 01/2026 230471C, exp. date 01/2026 230288C, exp. date 01/2026

Where it was sold

US Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0388-2025
Classification
Class II
Status
Ongoing
Recall initiated
Apr 14, 2025
FDA report date
Apr 30, 2025
Quantity
343,344 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Breckenridge Pharmaceutical, Inc

Original FDA data

Every field from FDA enforcement report D-0388-2025, exactly as published.

Show all FDA fields
City
Berlin
State
CT
Status
Ongoing
Country
United States
Event ID
96707
Address
15 Massirio Dr Ste 201
Code information
Lot # 230201C, exp. date 01/2026 230471C, exp. date 01/2026 230288C, exp. date 01/2026
Postal code
06037-2352
Report date
Apr 30, 2025
Product type
Drugs
Recall number
D-0388-2025
Classification
Class II
Recalling firm
Breckenridge Pharmaceutical, Inc
Product quantity
343,344 bottles
Reason for recall
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922
Distribution pattern
US Nationwide.
Recall initiation date
Apr 14, 2025
Initial firm notification
Letter
Center classification date
Apr 22, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0388-2025, published Apr 30, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls